Two Major Trials Show EGFR Inhibitors Fail to Improve Outcomes in Head and Neck Cancer
Key Insights
The IHN01 phase III trial found that adding nimotuzumab to adjuvant cisplatin-chemoradiotherapy did not significantly improve disease-free survival or overall survival in resected high-risk head and neck squamous cell carcinoma patients.
The DAHANCA19 trial demonstrated that zalutumumab combined with primary curative radiotherapy failed to improve loco-regional control, disease-specific survival, or overall survival in head and neck cancer patients.
Both studies suggest that EGFR (search)-targeting antibodies do not provide additional clinical benefit when added to standard chemoradiotherapy regimens, despite acceptable tolerability profiles.
Two landmark phase III trials have delivered disappointing results for EGFR (search)-targeting antibodies in head and neck squamous cell carcinoma (HNSCC), with both nimotuzumab and zalutumumab failing to demonstrate survival benefits when added to standard chemoradiotherapy regimens.
IHN01 Trial: Nimotuzumab Falls Short in Adjuvant Setting
The IHN01 trial, presented at ESMO 2025 by N. Gopalakrishna Iyer, tested whether adding nimotuzumab to adjuvant cisplatin-based chemoradiotherapy could improve outcomes in high-risk HNSCC patients following curative-intent surgery. This double-blind, placebo-controlled study enrolled 422 patients across 26 centers in 12 countries between November 2009 and October 2018.
Patients received postoperative chemoradiotherapy comprising radiotherapy plus either cisplatin 100 mg/m² every 3 weeks for 3 cycles or 30 mg/m² weekly for 7 cycles, randomized to receive either weekly nimotuzumab 200 mg or placebo for 8 weeks. After a median follow-up of 61 months, the results showed no significant improvement in the co-primary endpoints.
Disease-free survival showed failure in 44% of nimotuzumab patients versus 45% in the placebo group, with a hazard ratio of 0.94 (95% CI 0.70-1.25), which was not statistically significant. Overall survival demonstrated deaths in 30% versus 35% respectively, with a hazard ratio of 0.84 (95% CI 0.60-1.18), also not reaching significance.
The safety profile was acceptable, with grade ≥3 adverse events occurring in 59% of patients overall, with 27% considered study-drug related. Safety profiles were similar between treatment arms. Notably, weekly cisplatin was associated with fewer grade ≥3 adverse events compared to 3-weekly dosing, without differences in disease-free survival or overall survival between schedules.
DAHANCA19 Trial: Zalutumumab Shows No Benefit in Primary Treatment
The DAHANCA19 trial, conducted by the Danish Head and Neck Cancer study group and Oslo University Hospital, evaluated zalutumumab in the primary treatment setting. This randomized, open-label, two-armed phase III study enrolled 608 eligible patients with biopsy-verified HNSCC of the oral cavity, pharynx, and larynx between November 2007 and June 2012.
Both study arms received primary accelerated radiotherapy (predominantly 66-68 Gy, 2 Gy/fraction, 6 fractions/week) with concomitant daily hypoxic radiosensitization using nimorazole. Patients with Stage III-IV carcinomas additionally received weekly cisplatin (40 mg/m²). The zalutumumab arm received the same treatment plus zalutumumab at 8 mg/kg, with the first dose given a week before radiotherapy and continuing weekly throughout treatment.
After a median follow-up of 59 months, the results were similarly disappointing. The 5-year loco-regional failure rate was 24% in the zalutumumab arm compared to 18% in the control arm, with a hazard ratio of 1.16 (95% CI, 0.84-1.59), indicating no reduction in failure with zalutumumab.
Disease-specific survival showed no difference between arms (HR 1.04; 95% CI, 0.73-1.50), with 60-month disease-specific survival rates of 80% for zalutumumab versus 81% for control. Overall survival similarly showed no statistically significant difference (HR 1.21; 95% CI, 0.91-1.61), with actuarial survival rates at 60 months of 65% in the zalutumumab arm versus 71% in the control arm.
Safety and Tolerability Considerations
While both EGFR (search) inhibitors demonstrated acceptable safety profiles, they were associated with increased toxicity. In the DAHANCA19 trial, zalutumumab led to increased acute toxicity, notably a significant rise in in-field skin reactions and a more universal rash experienced by 92% of patients in the zalutumumab arm. Patients receiving zalutumumab had a significantly lower chance of completing the full five cycles of cisplatin, suggesting that added acute toxicity might have limited concurrent chemotherapy administration.
Clinical Implications and Future Directions
These findings align with other studies, including the RTOG 0522 trial and Concert 1 phase II study, which similarly found that adding EGFR (search) inhibitors like cetuximab or panitumumab to chemoradiotherapy for HNSCC did not improve outcomes but increased toxicity. The results suggest potential overlap in mechanisms of action between EGFR inhibitors and other components of chemoradiotherapy, negating additional benefit.
The IHN01 investigators noted that their study "underscores that rigorous, investigator-initiated multicenter trials—leveraging independent QA—can efficiently test escalation strategies beyond cooperative groups and help refine standard adjuvant care." Both trials provide definitive evidence against the routine use of EGFR (search) inhibitors in HNSCC treatment, regardless of HPV/p16 status or other patient characteristics.
These results will likely influence future treatment guidelines and help avoid unnecessary toxicity for patients, while highlighting the continued need for novel therapeutic approaches in head and neck cancer treatment.